| [1] |
Reiter C, Frhlich T, Zeino M, et al. New efficient artemisinin derived agents against human leukemia cells, human cytomegalovirus and Plasmodium falciparum: 2nd generation 1,2,4-trioxane-ferrocene hybrids[J]. Eur J Med Chem, 2015, 97: 164-172.
|
| [2] |
] 宋芳华, 罗 蒙, 范 宁, 等. 双氢青蒿素联合吉非替尼抑制肺腺癌细胞周期和迁移能力的体外研究[J]. 武警医学, 2019, 30(3): 228-232.
|
| [3] |
] Li Z, Shi X, Liu J, et al. Artesunate prevents type 1 diabetes in NOD mice mainly by inducing protective IL-4-producing T cells and regulatory T cells[J]. FASEB J, 2019, 33(7): 8241-8248.
|
| [4] |
] Yu L, Chen J F, Shuai X, et al. Artesunate protects pancreatic beta cells against cytokine-induced damage via SIRT1 inhibiting NF-κB activation[J]. J Endocrinol Invest, 2016, 39(1): 83-91.
|
| [5] |
] Li J, Casteels T, Frogne T, et al. Artemisinins target GABAA receptor signaling and impair α cell identity[J]. Cell, 2017, 168(1-2): 86-100,e15.
|
| [6] |
] van der Meulen T, Lee S, Noordeloos E, et al. Artemether does not turn α Cells into β cells[J]. Cell Metab, 2018, 27(1): 218-225, e4.
|
| [7] |
] Gnudi L, Richard J, Long D A. Diabetic nephropathy: perspective on novel molecular mechanisms[J]. Trends Endocrinol Metab, 2016, 27(11): 820-830.
|
| [8] |
] Lim A K, Tesch G H. Inflammation in diabetic nephropathy[J]. Mediators Inflamm, 2012, 2012: 146154.
|
| [9] |
] Bai L, Li J, Li H, et al. Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-κB signaling and NLRP3 inflammasome activation by exosomes in rats[J]. Biochem Pharmacol, 2019, 169: 113619.
|
| [10] |
Bai L, Li H, Li J, et al. Immunosuppressive effect of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via regulating the differentiation of CD4+ T cell subsets in rats[J]. Int Immunopharmacol, 2019, 70:313-323.
|
| [11] |
Wen Y, Pan M M, Lv L L, et al. Artemisinin attenuates tubulointerstitial inflammation and fibrosis via the NF-κB/NLRP3 pathway in rats with 5/6 subtotal nephrectomy [J]. J Cell Biochem, 2019, 120(3): 4291-4300.
|
| [12] |
周凤娇, 苏彦君, 张丽坤, 等. 青蒿素对糖尿病大鼠肾组织NF-κB的DNA结合活性升高的抑制作用[J]. 现代中西医结合杂志, 2014, 23(19): 2075-2076, 2079.
|
| [13] |
聂 寒, 苏 珂, 龙 艳, 等. 青蒿琥酯对糖尿病肾病大鼠肾组织Toll样受体4及白细胞介素-8表达的影响[J]. 天津医药, 2015,43(4): 356-360.
|
| [14] |
张丽坤, 周凤娇, 苏彦君, 等. 青蒿素对糖尿病大鼠肾脏保护作用机制研究[J]. 现代中西医结合杂志, 2014, 23(26): 2862-2863, 2964.
|
| [15] |
张丽坤, 苏彦君, 周凤娇, 等. 青蒿素对实验性糖尿病大鼠肾脏PDGF-B表达上调的影响[J]. 现代中西医结合杂志, 2014,23(13):1392-1393,1396.
|
| [16] |
Zhang Y, Li H, Zhu J, et al. Role of artesunate in TGF-β1 induced renal tubular epithelial mesenchymal transdifferentiation in NRK-52E cells[J]. Mol Med Rep, 2017, 16(6):8891-8899.
|
| [17] |
Han P, Wang Y, Zhan H, et al. Artemether ameliorates type 2 diabetic kidney disease by increasing mitochondrial pyruvate carrier content in db/db mice[J]. Am J Transl Res, 2019, 11(3): 1389-1402.
|
| [18] |
李俊龙, 曹新冉, 王 莹, 等. 青蒿素对糖尿病心肌病大鼠心功能及纤维化的影响.[J]. 上海中医药杂志, 2016, 50(3):70-73.
|
| [19] |
Lee I S, Ryu D K, Lim J, et al. Artesunate activates Nrf2 pathway-driven anti-inflammatory potential through ERK signaling in microglial BV2 cells[J]. Neurosci Lett, 2012, 509(1):17-21.
|
| [20] |
梁国标, 郭润民, 吴 铿. 氧化应激与自噬相互作用在糖尿病心肌病发病中的研究现状[J]. 中国医学创新, 2016,13(32):132-136.
|
| [21] |
Ahmad W, Khan I, Khan M A, et al. Evaluation of antidiabetic and antihyperlipidemic activity of Artemisia indica linn (aeriel parts) in Streptozotocin induced diabetic rats [J]. J Ethnopharmacol, 2014, 151(1): 618-623.
|
| [22] |
姜宏卫, 辛亚凯, 郭 宇, 等. 蒿甲醚在db/db小鼠中抗糖尿病及抗肥胖的作用[J]. 中国中西医结合杂志, 2018, 38(10): 1209-1214.
|
| [23] |
Gu Y, Wang X, Wang X, et al. Artemisinin attenuates post-infarct myocardial remodeling by down-regulating the NF-κB pathway[J]. Tohoku J Exp Med, 2012, 227(3):161-170.
|
| [24] |
Xiong Z, Sun G, Zhu C, et al. Artemisinin, an anti-malarial agent, inhibits rat cardiac hypertrophy via inhibition of NF-κB signaling[J]. Eur J Pharmacol, 2010, 649(1-3): 277-284.
|
|
|
2020, Vol. 31 
